AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28206806 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training intervention led by military-connected facilitators
Number of subjects: 0
Study 28206806 — intervention group
Group type: COMPARATOR
Intervention: Parent training intervention led by civilian facilitators
Number of subjects: 0
Study 28206806 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training intervention (both groups)
Number of subjects: 0
Study 26035319 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV monotherapy with either lamivudine or emtricitabine, N=56
Number of subjects: 115
Study 26035319 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV dual therapy with tenofovir disoproxil fumarate (TDF) + lamivudine or emtricitabine, N=59
Number of subjects: 115
Study 26035319 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV dual therapy
Number of subjects: 115
Study 23930028 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast pranayama (Group 1) - Kapalabhati, Bhastrika, Kukkuriya Pranayama
Number of subjects: 90
Study 23930028 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow pranayama (Group 2) - Nadishodhana, Savitri, Pranav Pranayama
Number of subjects: 90
Study 23930028 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 90
Study 21774826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) given once a day for three days
Number of subjects: 384
Study 21774826 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL) given twice a day for three days
Number of subjects: 384
Study 21774826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 384
Study 21774826 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 384
Study 21774826 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 384
Study 19723787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 327
Study 19723787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 327
Study 19723787 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and CBT
Number of subjects: 327
Study 19723787 — intervention group
Group type: COMPARATOR
Intervention: No treatment during follow-up (naturalistic follow-up)
Number of subjects: 327
Study 16698862 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g
Number of subjects: 18
Study 16698862 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg + Acetaminophen 1 g
Number of subjects: 18
Study 16698862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 14507834 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hCG
Number of subjects: 73
Study 14507834 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant LH
Number of subjects: 73
Study 14507834 — intervention group
Group type: COMPARATOR
Intervention: Individually tailored IVM treatments (control group)
Number of subjects: 73
Study 10775962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (intravenously 5 mg/hour for one week)
Number of subjects: 22
Study 10775962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8829017 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg QD, titrated to losartan/HCTZ 50 mg/12.5 mg QD after 4 weeks, then to 50 mg/25 mg QD after 8 weeks)
Number of subjects: 223
Study 8829017 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS (30 mg QD, titrated to 60 mg QD after 4 weeks, then to 90 mg QD after 8 weeks)
Number of subjects: 223
Study 8829017 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 223
Study 1331482 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose carboplatin and etoposide with autologous bone marrow transplantation
Number of subjects: 40
Study 1331482 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose carboplatin and etoposide with autologous bone marrow transplantation plus oxazaphosphorine (usually cyclophosphamide)
Number of subjects: 40
Study 1331482 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and etoposide alone
Number of subjects: 40
Study 3858229 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol-containing dentifrice (10% xylitol) with conventional treatment
Number of subjects: 990
Study 3858229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride systemic administration (in milk or drinking water) with conventional treatment
Number of subjects: 990
Study 3858229 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental treatment procedures alone (fluoride-free dentifrices)
Number of subjects: 990
Study 31122994 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week computerised cognitive training programme (five × 30 min sessions per week)
Number of subjects: 60
Study 31122994 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 60
Study 29510970 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought Spot platform (eHealth intervention)
Number of subjects: 41
Study 29510970 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory design research (PDR) methods
Number of subjects: 41
Study 29510970 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshops for feedback on platform usability
Number of subjects: 41
Study 25950679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolder bar attachments
Number of subjects: 46
Study 25950679 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator attachments
Number of subjects: 46
Study 25950679 — intervention group
Group type: EXPERIMENTAL
Intervention: Original dentures with Dolder bar
Number of subjects: 46
Study 25950679 — intervention group
Group type: EXPERIMENTAL
Intervention: Original dentures with Locator
Number of subjects: 46
Study 25088638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical compression of the lid margin (Group A)
Number of subjects: 306
Study 25088638 — intervention group
Group type: COMPARATOR
Intervention: No lid scrubbing (Group B)
Number of subjects: 306
Study 22473250 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 38
Study 22473250 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 38
Study 22473250 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction + Resistance training (CR + RT)
Number of subjects: 38
Study 22473250 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 20148604 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive diabetes disease management program (DDMP) plus usual care
Number of subjects: 217
Study 20148604 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 217
Study 17200478 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for falls assessment
Number of subjects: 18
Study 17200478 — intervention group
Group type: EXPERIMENTAL
Intervention: History of falls in the past year
Number of subjects: 18
Study 17200478 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of gait or balance abnormalities
Number of subjects: 18
Study 17200478 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment, medication variables, decreased activities of daily living, impaired cognition
Number of subjects: 18
Study 17200478 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic hypotension
Number of subjects: 18
Study 16036001 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention using internet videoconferencing at 128 kbit/s
Number of subjects: 12
Study 12131252 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid provision (L‐lysine, L‐leucine, L‐valine, L‐phenylalanine, L‐threonine, L‐histidine, L‐isoleucine, and L‐methionine) with carbohydrates (dextrose, sucrose, and fructose) during a 12‐wk progressive knee extensor resistance training (PRT) program
Number of subjects: 17
Study 12131252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amino acid provision) during a 12‐wk progressive knee extensor resistance training (PRT) program
Number of subjects: 17
Study 10386022 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-I nasal inhalation and gargling (1% PVP-I solution, 2 times/day for 2 weeks)
Number of subjects: 30
Study 10386022 — intervention group
Group type: COMPARATOR
Intervention: Control group (gargling with PVP-I solution, 2 times/day for 2 weeks)
Number of subjects: 30
Study 10386022 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-I nasal inhalation (1% PVP-I solution, 2 times/day for 2 weeks) without chronic respiratory complications
Number of subjects: 30
Study 8767947 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic decompression
Number of subjects: 45
Study 8767947 — intervention group
Group type: COMPARATOR
Intervention: Open decompression
Number of subjects: 45
Study 1984743 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once a day) + Pancrease (four capsules three times a day)
Number of subjects: 9
Study 1984743 — intervention group
Group type: COMPARATOR
Intervention: Pancrease (two capsules three times a day)
Number of subjects: 9
Study 1984743 — intervention group
Group type: COMPARATOR
Intervention: Pancrease (four capsules three times a day)
Number of subjects: 9
Study 1984743 — intervention group
Group type: COMPARATOR
Intervention: Pancrease (two capsules three times a day) + Omeprazole
Number of subjects: 9
Study 6669627 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 0
Study 6669627 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg flunitrazepam
Number of subjects: 0
Study 6669627 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nitrazepam
Number of subjects: 0
Study 6669627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30609439 — intervention group
Group type: EXPERIMENTAL
Intervention: TG-C (TissueGene-C) at a dose of 3.0 × 10^7 cells
Number of subjects: 102
Study 30609439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 30666962 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve-guided complete revascularisation (FFR-CRV)
Number of subjects: 627
Study 30666962 — intervention group
Group type: COMPARATOR
Intervention: Infarct-related artery only (IRA only)
Number of subjects: 627
Study 26310513 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO mouthwash (50 IU/ml, 15 ml four times a day)
Number of subjects: 80
Study 26254056 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNFα therapy
Number of subjects: 915
Study 26254056 — intervention group
Group type: COMPARATOR
Intervention: Ileostomy
Number of subjects: 915
Study 26254056 — intervention group
Group type: COMPARATOR
Intervention: Pouch
Number of subjects: 915
Study 24350571 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Basic Parenting Programme
Number of subjects: 119
Study 24350571 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 119
Study 21422117 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted influenza H1N1/A/09 vaccine (2 doses)
Number of subjects: 65
Study 21422117 — intervention group
Group type: COMPARATOR
Intervention: AS03-adjuvanted influenza H1N1/A/09 vaccine (1 dose)
Number of subjects: 65
Study 18512789 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 gm/day)
Number of subjects: 5091
Study 18512789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5091
Study 16598442 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP treatment in hypertensive OSAS patients
Number of subjects: 69
Study 16598442 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP treatment in normotensive OSAS patients
Number of subjects: 69
Study 16598442 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive patients without OSAS)
Number of subjects: 69
Study 15381595 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of intravenous amoxicillin‐clavulanic acid
Number of subjects: 73
Study 15381595 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 73
Study 10703931 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (2 IU/m2/day = 0.67 mg/m2/day)
Number of subjects: 29
Study 10703931 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 29
Study 9077617 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 135
Study 9077617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 8397723 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dihydroxy-phenylalanine/carbidopa (100 mg/25 mg)
Number of subjects: 30
Study 8397723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3535601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin therapy
Number of subjects: 225
Study 3535601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 3389320 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 micrograms Se/d for 60 days)
Number of subjects: 16
Study 3389320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3389320 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 16
Study 28977406 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified reverse subclavian flap angioplasty (MRA), n=27
Number of subjects: 54
Study 28977406 — intervention group
Group type: COMPARATOR
Intervention: Extended end‐to‐end anastomosis (EEA), n=27
Number of subjects: 54
Study 28351093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight reduction intervention
Number of subjects: 97
Study 28351093 — intervention group
Group type: COMPARATOR
Intervention: Baseline Angiopoietin‐like protein 8/betatrophin
Number of subjects: 97
Study 28351093 — intervention group
Group type: COMPARATOR
Intervention: Circulating ANGPTL8/betatrophin
Number of subjects: 97
Study 25764613 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT)
Number of subjects: 30
Study 25764613 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound therapy (US)
Number of subjects: 30
Study 23791215 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser ablation of the prostate (HOLAP)
Number of subjects: 109
Study 23791215 — intervention group
Group type: COMPARATOR
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 109
Study 23791215 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HOLAP and PVP
Number of subjects: 109
Study 23791215 — intervention group
Group type: COMPARATOR
Intervention: PVP
Number of subjects: 109
Study 20605590 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic VIH
Number of subjects: 145
Study 20605590 — intervention group
Group type: EXPERIMENTAL
Intervention: Open VIH
Number of subjects: 145
Study 20605590 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical technique
Number of subjects: 145
Study 18222251 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 3014
Study 18222251 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 3014
Study 17076224 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 40
Study 17076224 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 40
Study 17076224 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 40
Study 14722683 — intervention group
Group type: EXPERIMENTAL
Intervention: LSO-PS (lutetium oxyorthosilicate/sodium iodide dual-head coincidence camera)
Number of subjects: 24
Study 14722683 — intervention group
Group type: COMPARATOR
Intervention: BGO-PET (gold standard)
Number of subjects: 24
Study 11770190 — intervention group
Group type: EXPERIMENTAL
Intervention: Climodien (estradiol valerate 2 mg plus dienogest 2 mg)
Number of subjects: 1501
Study 9283792 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 16
Study 9283792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9283792 — intervention group
Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 16
Study 20058464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative indwelling urethral catheter (IUC)
Number of subjects: 32
Study 20058464 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative catheter (NC)
Number of subjects: 32
Study 2941206 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 or 4 mg/day)
Number of subjects: 15
Study 2941206 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 or 80 mg/day)
Number of subjects: 15
Study 2941206 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 15
Study 31634724 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrating/processing positive memories
Number of subjects: 65
Study 31634724 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing/processing positive memories
Number of subjects: 65
Study 31634724 — intervention group
Group type: COMPARATOR
Intervention: Time-matched control
Number of subjects: 65
Study 29506970 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate 10 g daily
Number of subjects: 0
Study 29506970 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate 15 g daily
Number of subjects: 0
Study 29506970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29506970 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate (10 g or 15 g)
Number of subjects: 0
Study 27437723 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT group, n=9), therapy with a mirror box 5 days/week, 30 min/day, for 3 weeks
Number of subjects: 24
Study 27437723 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography-triggered neuromuscular stimulation (ES group, n=7), therapy of similar duration and frequency as MT group
Number of subjects: 24
Study 27437723 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (Control group, n=8)
Number of subjects: 24
Study 25493602 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among women using DMPA
Number of subjects: 4747
Study 25493602 — intervention group
Group type: COMPARATOR
Intervention: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among women using no hormonal contraception
Number of subjects: 4747
Study 25493602 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among men whose partners used DMPA
Number of subjects: 4747
Study 25493602 — intervention group
Group type: COMPARATOR
Intervention: PrEP (daily oral tenofovir and emtricitabine/tenofovir) among men whose partners used no hormonal contraception
Number of subjects: 4747
Study 23046807 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling session to reduce alcohol risk
Number of subjects: 0
Study 23046807 — intervention group
Group type: COMPARATOR
Intervention: Health education leaflet
Number of subjects: 0
Study 20657780 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese young adults
Number of subjects: 0
Study 20657780 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese young adults
Number of subjects: 0
Study 20657780 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian-Canadian young adults
Number of subjects: 0
Study 17854972 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor assessment of ventilation skills
Number of subjects: 826
Study 17854972 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor assessment of compressions
Number of subjects: 826
Study 17854972 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor assessment of compression depth
Number of subjects: 826
Study 17854972 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor assessment of hand placement
Number of subjects: 826
Study 15994719 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/day
Number of subjects: 542
Study 15994719 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg/day
Number of subjects: 542
Study 15994719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study 12354427 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine-induced hyperhomocysteinemia
Number of subjects: 18
Study 12354427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12354427 — intervention group
Group type: EXPERIMENTAL
Intervention: l-NMMA (0.3 mg/kg/min intravenously)
Number of subjects: 18
Study 11092491 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-field MR imaging with contrast enhancement (0.1 or 0.3 mmol/kg b.w. gadodiamide)
Number of subjects: 95
Study 11092491 — intervention group
Group type: COMPARATOR
Intervention: Clinical staging according to FIGO recommendations (1988)
Number of subjects: 95
Study 9488190 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 0
Study 9488190 — intervention group
Group type: EXPERIMENTAL
Intervention: International Nifedipine Trial of Antiatherosclerotic Therapy (INTACT)
Number of subjects: 0
Study 9488190 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Nicardipine Trial
Number of subjects: 0
Study 9488190 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS)
Number of subjects: 0
Study 8417552 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour dawn simulation peaking at 250 lux
Number of subjects: 22
Study 8417552 — intervention group
Group type: COMPARATOR
Intervention: 30-minute dawn simulation peaking at 0.2 lux
Number of subjects: 22
Study 3508629 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine
Number of subjects: 12
Study 3508629 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine
Number of subjects: 12
Study 3508629 — intervention group
Group type: COMPARATOR
Intervention: misoprostol
Number of subjects: 12
Study 3508629 — intervention group
Group type: COMPARATOR
Intervention: carbenoxolone
Number of subjects: 12
Study 30691421 — intervention group
Group type: EXPERIMENTAL
Intervention: ZemCAD intervention
Number of subjects: 141
Study 30691421 — intervention group
Group type: COMPARATOR
Intervention: Current care as usual (CAU)
Number of subjects: 141